Home ›

Drugs in the Queue

Cogane

Submitted Sun, 12/06/2009
in

A new BDNF inducer enters the pipeline.

An Ampakine Upregulates BDNF

Submitted Fri, 04/24/2009
in

An ampakine, a modulator of glutamate receptors, reduced memory and learning problems in HD mice.

CERE-120 (AAV-Neurturin) is neuroprotective in HD mouse model

Submitted Thu, 04/23/2009
in
Neurturin. a neurotrophic factor, protected striatal and cortical neurons in an HD mouse model.

Disappointing results from a Phase II trial of CERE-120 for PD patients

Submitted Thu, 04/23/2009
in
Neurturin, a neurotrophic factor, failed to yield meaningful improvement in PD patients.

Amarin files new drug application for AMR 101 in Europe

Submitted Wed, 04/08/2009
in
Ethyl-EPA remains in the drug development pipeline.

The ACR-16 trial is enrolling participants

Submitted Tue, 02/03/2009
in
An interview with lead investigator Dr. Karl Kieburtz.

Surprising Finding Points to Possible Treatment for Huntington Disease

Submitted Sat, 01/31/2009
in

Drugs that increase the activity of PPAR-delta are added to the pipeline of potential treatments.

Long term antipsychotic use in elderly AD patients

Submitted Fri, 01/09/2009
in
Elderly patients with AD on antipsychotic meds have a higher death rate.

Long term tetrabenazine use

Submitted Thu, 01/01/2009
in
In an Italian study, TBZ improved chorea for most patients; over time the magnitude of the benefit declined somewhat.

Ethyl-EPA research report published

Submitted Mon, 12/15/2008
in
Ethyl-EPA is still in the research pipeline.
Syndicate content